Literature DB >> 17229654

Severe pulmonary complications after initial treatment with Rituximab for the Asian-variant of intravascular lymphoma.

Shang-Ju Wu, Wen-Chien Chou, Bo-Sheng Ko, Hwei-Fang Tien.   

Abstract

Rituximab improves response to treatment and outcome for patients with CD20+ B-cell lymphoma. Herein, however, we report the occurrence of severe pulmonary complications shortly after rituximab infusion in three patients with the newly diagnosed Asian variant of intravascular lymphoma. It is suggested that patients with this subtype of lymphoma are monitored carefully for possible drug reactions during the use of rituximab.

Entities:  

Mesh：

Substances：

Year:  2007        PMID： 17229654     DOI： 10.3324/haematol.10561

Source DB:  PubMed          Journal:  Haematologica        ISSN： 0390-6078            Impact factor:   9.941


  7 in total

1.  Intravascular large B cell lymphoma: proposed of the strategy for early diagnosis and treatment of patients with rapid deteriorating condition.

Authors:  Yasufumi Masaki; Lingli Dong; Akio Nakajima; Haruka Iwao; Miyuki Miki; Nozomu Kurose; Eriko Kinoshita; Takayuki Nojima; Toshioki Sawaki; Takafumi Kawanami; Masao Tanaka; Kumiko Shimoyama; Changi Kim; Masaaki Fukutoku; Hiroshi Kawabata; Toshihiro Fukushima; Yuko Hirose; Tomoo Takiguchi; Susumu Konda; Susumu Sugai; Hisanori Umehara
Journal:  Int J Hematol       Date:  2009-04-14       Impact factor: 2.490

2.  Chemotherapy-resistant intravascular lymphoma accompanied by ADAMTS13 inhibitor successfully treated with rituximab.

Authors:  Masatoshi Kanno; Shinobu Nakamura; Makoto Kawahara; Satoshi Ueno; Hirokazu Nakamine; Masanori Matsumoto; Yoshihiro Fujimura
Journal:  Int J Hematol       Date:  2008-08-19       Impact factor: 2.490

3.  Evaluation of organ involvement in intravascular large B-cell lymphoma by 18F-fluorodeoxyglucose positron emission tomography.

Authors:  Kazuyuki Shimada; Hiroshi Kosugi; Satoko Shimada; Hiroto Narimatsu; Yoshitsugu Koyama; Nobuaki Suzuki; Masaaki Yuge; Hironori Nishibori; Yosuke Iwata; Shigeo Nakamura; Tomoki Naoe; Tomohiro Kinoshita
Journal:  Int J Hematol       Date:  2008-05-22       Impact factor: 2.490

4.  Rituximab-induced hypersensitivity pneumonitis.

Authors:  Adriano R Tonelli; Richard Lottenberg; Robert W Allan; P S Sriram
Journal:  Respiration       Date:  2008-10-09       Impact factor: 3.580

5.  Rituximab-induced bronchiolitis obliterans organizing pneumonia.

Authors:  Ahmet B Ergin; Nancy Fong; Hamed A Daw
Journal:  Case Rep Med       Date:  2012-06-19

6.  Rituximab and cytokine release syndrome.

Authors:  Hrishikesh S Kulkarni; Pashtoon Murtaza Kasi
Journal:  Case Rep Oncol       Date:  2012-03-20

7.  Treatment strategy for reducing the risk of rituximab-induced cytokine release syndrome in patients with intravascular large B-cell lymphoma: a case report and review of the literature.

Authors:  Katsuhiro Makino; Jumi Nakata; Satoru Kawachi; Tatsuyuki Hayashi; Atsuo Nakajima; Munehiro Yokoyama
Journal:  J Med Case Rep       Date:  2013-12-30
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.